Fulgent Genetics
Combines hereditary-cancer and pathology testing with a nanoencapsulated cancer-drug pipeline in clinical trials.
$19.61
After-hours close−0.01 (−0.05%)
At close$19.62(−1.65%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 56.52%16.05M sharesInsiders 9.47%2.69M sharesOther 34.01%9.66M shares
Shares outstanding 28.40M · Float 17.03M · 60.0% free float
Institutions13F, as of Jun 30, 2026
147 holders · 16.05M shares · 24 new positions · 65 increased · 53 reduced · 37 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.29M | 8.05% | −487.9K | Aug 7, 2026 |
| Acadian Asset Management LLC | 1.02M | 3.58% | −216.0K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 789.5K | 2.78% | −90.7K | Aug 13, 2026 |
| Jacobs Levy Equity Management, Inc | 782.1K | 2.75% | +425.8K | Aug 14, 2026 |
| JPMorgan Chase & Co | 756.6K | 2.66% | +296.2K | Aug 12, 2026 |
| Diametric Capital, LP | 697.8K | 2.46% | +336.7K | Aug 14, 2026 |
| Ameriprise Financial Inc | 670.1K | 2.36% | +106.7K | Aug 14, 2026 |
| Dimensional Fund Advisors LP | 625.4K | 2.20% | −46.3K | Aug 11, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Barclays PLC | 7.57% | 2.34M | 13G | May 13, 2025 ↗ |
| BlackRock, Inc. | 5.90% | 1.82M | 13G | Apr 3, 2025 ↗ |
| Ramya Rao | 5.42% | 1.66M | 13G | Feb 7, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Hanlin Gao | officer: Chief Scientific Officer | 987.8K | 3.48% | Aug 28, 2026 |
| Ming Hsieh | director, 10 percent owner, officer: Chief Executive Officer | 890.3K | 3.13% | Aug 28, 2026 |
| Jian Xie | officer: President and COO | 362.1K | 1.27% | Aug 28, 2026 |
| Paul Kim | officer: CFO and Treasurer | 358.6K | 1.26% | Aug 28, 2026 |
| Linda Dong | director | 38.8K | 0.14% | May 18, 2026 |
| Regina E. Groves | director | 28.1K | 0.10% | May 18, 2026 |
| Michael Nohaile | director | 24.6K | 0.09% | May 18, 2026 |
2 ten-percent owners hold 9.92M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (35.1K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 27, 2026 | Hanlin Gaoofficer: Chief Scientific Officer | Sale | 939 | $19.91 | 987,790 |
| Aug 27, 2026 | Jian Xieofficer: President and COO | Sale | 1,193 | $19.91 | 362,051 |
| May 27, 2026 | Hanlin Gaoofficer: Chief Scientific Officer | Sale | 945 | $17.60 | 992,062 |
| May 27, 2026 | Jian Xieofficer: President and COO | Sale | 1,201 | $17.60 | 369,751 |
| Dec 2, 2025 | Hanlin Gaoofficer: Chief Scientific Officer | Sale | 1,075 | $28.33 | 952,890 |
| Dec 2, 2025 | Jian Xieofficer: President and COO | Sale | 1,140 | $28.33 | 336,749 |
| Nov 28, 2025 | Hanlin Gaoofficer: Chief Scientific Officer | Sale | 943 | $29.57 | 953,965 |
| Nov 28, 2025 | Jian Xieofficer: President and COO | Sale | 1,198 | $29.57 | 337,889 |
| Nov 24, 2025 | Hanlin Gaoofficer: Chief Scientific Officer | Sale | 535 | $30.47 | 954,908 |
| Nov 24, 2025 | Jian Xieofficer: President and COO | Sale | 681 | $30.47 | 339,087 |
CongressHouse and Senate disclosures
Not reported.